title: HIV-1 Eradication: Early Trials (and Tribulations).
abstract: Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with access to treatment. However, ART does not lead to viral eradication owing to the persistence of replication-competent, unexpressed proviruses in long-lived cellular reservoirs. The potential for long-term drug toxicities and the lack of access to ART for most people living with HIV-1 infection have fueled scientific interest in understanding the nature of this latent reservoir. Exploration of HIV-1 persistence at the cellular and molecular level in resting memory CD4(+) T cells, the predominant viral reservoir in patients on ART, has uncovered potential strategies to reverse latency. We review recent advances in pharmacologically based 'shock and kill' HIV-1 eradication strategies, including comparative analysis of early clinical trials.
authors.affiliation: Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Spivak
authors.affiliation: Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: vicente.planelles@path.utah.edu.
authors.forename: Vicente
authors.initials: V
authors.lastname: Planelles
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D060740:Disease Eradication; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D017735:Virus Latency / Q000187:drug effects